Clients & Success Stories

Success Stories

Driving Global Success for Healthcare Innovators

We partner with biotech and MedTech innovators to bring their vision to global markets. From regulatory breakthroughs to strategic deals, our success is measured in client growth. Explore how we help companies expand, adapt, and thrive internationally.

Success Story 1: Nano Cures – Middle East Expansion

Challenge

Nano Cures sought to enter the Middle Eastern market but lacked the regulatory insight and local partners required to move quickly and safely.

Our Solution

Crassus built a regulatory roadmap, secured a strategic distribution partner in the Gulf region, and provided localized marketing guidance.

Result

Product launch completed ahead of schedule with rapid regional adoption. Nano Cures now sees the Middle East as one of its fastest-growing territories.

Success Story 2: MedVanta – Balkan Market Penetration

Challenge

MedVanta, a mid-sized U.S. MedTech company, struggled with fragmented Balkan regulations and inconsistent partner leads.

Our Solution

We streamlined regulatory navigation across Serbia, Croatia, and Bosnia and negotiated a regional joint venture on their behalf.

Result

Sales increased by 40% in Q2 following launch, with efficient onboarding and clear regulatory compliance across multiple markets.

Success Story 3: BioTrace – Market Intelligence & Strategy

Challenge

BioTrace had a strong diagnostic product but lacked knowledge of North African healthcare systems and procurement channels.

Our Solution

Crassus provided a comprehensive market intelligence report, cultural briefings, and facilitated connections with decision-makers in Morocco and Egypt.

Result

BioTrace secured its first tender contract in the region and established a strong foothold for continued expansion.

Want to be our next success story

Ready to take your healthcare innovation global?

Every market breakthrough starts with the right partner. At Crassus, we turn international ambitions into proven success stories. Yours could be next.